 The metabolic enzyme PFKFB4 is early and strongly upregulated by 1α,25(OH) 2 D 3 in human differentiating monocytes.
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Dendritic cells, 1α,25(OH) 2 promote the development of tolDCs. 6 TolDCs generated by 1α,25(OH) 2 D 3 (1,25D 3 -DCs) have a stable maturation-resistant semi-mature phenotype characterized by a reduced expression of antigen-presenting and co-stimulatory molecules such as CD80, CD86, and a diminished secretion of pro-inflammatory cytokines such as IL-12 and IL-23 . [7] [8] [9] Moreover, the expression of inhibitory molecules such as the immunoglobulin-like transcript 3 (ILT-3 or CD85k) and the programmed death-ligand 1 (PD-L1 or CD274), both members of the B7 family of receptors that negatively influence T cell activation, is upregulated and the production of tolerogenic cytokines such as IL-10 and tumor necrosis factor (TNF)-α is enhanced in 1,25D 3 -DCs. 8, 10, 11 In this way, 1,25D 3 -DCs induce T cell hypo-responsiveness and allow a shift from T helper (Th)1-and Th17-mediated inflammatory responses towards Th2 cells and Tregs. 7, 10, 11 A major hallmark of 1,25D 3 -DCs is the introduction of antigen-specificity by pulsing these cells with antigen, consequently strengthening their therapeutic potential. In animal models, in vivo transfer of antigen-pulsed 1,25D 3 -DCs prevents allograft rejection and ameliorates symptoms of autoimmunity. 12 Clinical trials are ongoing (e.g. clinicaltrials.gov, NCT02903537). 9, 13 Although the phenotypic alterations induced by 1α,25(OH) 2 to specific vitamin D responsive element (VDRE) sequences in the promoter region of target genes. 14 However, this view of direct transcriptional regulation of immune genes is challenged by our previous study. A microarray analysis performed on differentiating monocytes exposed to 1,25(OH) 2 D 3 showed an initial and strong upregulation of metabolism-related gene expression after 4h, while the expression level of many other immune-related genes were only affected after 24h. 15 This implicates that when 1α,25(OH) 2 D 3 engages the VDR, the ensuing VDR signalling events promote the rapid transcriptional activation of multiple metabolic pathways involved in glycolysis and OXPHOS, which have an influence on the immune phenotype. To date, the contribution of this altered energy metabolism to the induction of the changes in phenotype and function of the 1,25D 3 -DC remains unclear.
8,15
Based on transcriptome analysis of 1,25D 3 -DCs, we identified the glycolytic enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB) 4 as a central 1α,25(OH) 2 D 3 target. PFKFB4 is a bifunctional glycolytic enzyme that synthesizes and degrades fructose-2,6-biphosphate (F-2,6-BP), an allosteric activator of phosphofructokinase-1 (PFK-1). 16 PFK-1 is the first rate-limiting enzyme of the glycolysis and therefore an important metabolic sensor. As the PFKFB4 enzyme is able to regulate glucose metabolism via PFK-1, understanding its specific role in the metabolic reprogramming observed in 1,25D 3 -DCs is important to determine the molecular mechanisms by which 1α,25(OH) 2 D 3 acts. Here we show that inhibition of PFKFB4 activity reduced glucose metabolism and prevented the 1α,25(OH) 2 D 3 -mediated upregulation of the inhibitory molecule ILT-3 and the tolerogenic marker CD52, as well as the induction of regulatory cytokines IL-10, TGF-β and TNF-α in human monocyte-derived DCs. As a result, PFKFB4 inhibition impaired the capacity of 1,25D 3 -DCs to induce functional Tregs.
MATERIALS AND METHODS

In vitro generation of human monocyte-derived dendritic cells
Human monocytes were freshly isolated and differentiated into DCs as described 8 , with the approval of the ethics committee (S-number 52679) of the University hospital of Leuven (UZ Leuven, Leuven, Belgium). In brief, peripheral blood mononuclear cells (PBMCs) were isolated by Lymphoprep gradient centrifugation (Alere Technologies AS, Oslo, Norway) from blood from healthy donors. Monocytes were purified from PBMCs by positive selection using the CD14 Microbeads Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to manufacturer's protocol. Isolated monocytes were cultured in differentiation medium containing 500 IU/ml human recombinant IL-4 (Gentaur, Kampenhout, Belgium) and 800 IU/ml human recombinant GM-CSF (Gentaur). Medium and cytokines were refreshed on day 3. On day 6, medium was refreshed and maturation was induced in the presence of 800 IU/ml GM-CSF (Gentaur), 100 ng/ml LPS (Sigma-Aldrich, St. Louis, MO, USA) and 1,000 IU/ml human recombinant IFN- (Roche, Basel, Switzerland). calculated as the ratio between the target and the β-actin loading control, after background correction.
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Metabolic tests
Glucose and lactate medium content
The glucose and lactate content in the supernatants of the DC cultures was determined using the Olympus AU640® clinical Chemistry System for in vitro diagnostic use with the glucose and lactate reagent kits (Beckman Coulter, Analis, Suarlée, Belgium), according to manufacturer's guidelines.
Glycolytic flux
Glycolytic flux was determined as previously described in 18 . 
Seahorse technology
DCs were seeded at 6 
Metabolomics
For metabolic tracing, DCs were cultured for 24 to 72 hours in the presence of [U-
13
C]-glucose (Cambridge isotope laboratories, Inc. Tewksbury, MA, USA) after which they were washed with ice-cold 0.9% NaCl. Cellular metabolites were extracted with 500 µl 80% methanol (overnight at -80°C). The metabolic tracing was performed on day 4-6 of the DC culture. These time points were chosen based on a pilot experiment and exclude any confounding impact of maturation stimuli on intracellular glucose metabolism. Next the extracts were centrifuged at 4°C for 15 min at 20,000 g. The supernatant was dried using a vacuum centrifuge. To the capillary temperature of 320 °C, sheath gas at 50.0, auxiliary gas at 10.0. The AGC target was set at 3e6 using a resolution of 140.000, with a maximum IT fill time of 512 ms. Data collection was performed using the Xcalibur software (Thermo Scientific). Results were normalized to total protein content.
F-2,6-BP measurement
For F-2,6-BP determination, mature DCs were washed with ice-cold 0.9% NaCl and metabolites were extracted with 300 µl 80% methanol. Next the extracts were centrifuged at 4°C for 15 min at 20,000 g. The supernatant was dried using a vacuum centrifuge. To the dried fractions were further processed and the F-2,6-BP was determined by LC-MS as described above.
PFK Activity Assay
The PFK enzyme activity in DC samples was determined using the PFK Activity Colorimetric Assay Kit (BioVision, Milpitas, CA, USA) according to manufacturer's guidelines and normalized to total protein content. 
Flow cytometry analysis of surface markers on human dendritic cells
Measurement of indoleamine-2,3-dioxygenase (IDO)
Secretion levels of IDO in the DC culture supernatant was determined by the RayBio® Human IDO ELISA Kit (RayBiotech, Norcross, GA, USA).
In vitro allogenic T cell proliferation and flow cytometry analysis
CD3
+ T cells were isolated from PBMCs of healthy donors using the Pan T Cell Kit II (Miltenyi Biotec), following the manufacturer's guidelines. Purified CD3 + T cells were labelled with 1 µM carboxyfluorescein succinimidyl ester (CFSE; Thermo Fisher Scientific/eBioscience) and co-cultured with DCs in a 1:10 DC:T cell ratio for 4 days.
T cell proliferation was determined in both CD4 + and CD8 + T cell subsets (antibodies from eBioscience).
Doublets were excluded based on signal height and widths. Dead cells were stained by Zombie Yellow Fixable Viability Kit (BioLegend) and excluded from analysis. Samples were acquired on a Gallios TM Flow Cytometer (Beckman Coulter) and analyzed with the FlowJo software v10.1 (TreeStar).
Induction of antigen-specific regulatory T cells and suppression assay
T cell lines were induced as previously described 11 . In brief, CD4 + T cells were isolated from PBMCs using the Human CD4 + T cell Isolation Kit (Miltenyi Biotec), according to manufacturer's specifications. 1 x 10 6 purified CD4 + T cells were co-cultured with vehicle-and 1,25D 3 -DCs from an haplo-identical donor at a 1:10 DC:T cell ratio in IMDM (Thermo Fisher Scientific/Gibco) with 10 % human serum (Biowest, Nuaillé, France). After 5 days, T cells were recovered and rested for 2 days in the presence of 10 ng/ml IL-7 and 5 ng/ml IL-15 (both from Genscript, Nanjing, China). On day 7 after primary stimulation, the CD4 + T cells were re-stimulated under the same conditions. T cells stimulated with 1,25D 3 
Characterization of regulatory T cells by flow cytometry
Treg lines were characterized by flow cytometry. Staining of surface proteins was performed with the following conjugated antibodies: CD4, CD49b (eBioscience/Thermo Fisher), CD25 (Miltenyi Biotec), CD127 (BD Biosciences), LAG-3 (Biolegend). For the FoxP3 intracellular staining, cells were fixed and permeabilized using Fig. 4 ). Samples were acquired on a BD Symphony flow cytometer (BD Biosciences) and analyzed with FlowJo software v.10.1 (TreeStar).
Statistics
The normality of all datasets was tested. When data was normally distributed, either unpaired Student's t test, One sample t test or one-way ANOVA with Sidak's post-test for multiple comparison was used. When data was not normally distributed, statistical significance was determined using the Mann-Whitney U test or the Kruskal-Wallis test with subsequent Dunn's post-test. All statistical analyses were performed using GraphPad
Prism software (GraphPad Software, La Jolla, CA, USA). Significance was defined as *p < 0.05; **p < 0.01; ***p < 0.001; **** p < 0.0001.
RESULTS
1α,25(OH) 2 D 3 rapidly induces expression of the glycolytic enzyme PFKFB4 leading to a metabolic reprogramming towards aerobic glycolysis and glucose oxidation in tolerogenic dendritic cells.
Our previous transcriptomic analysis of human differentiating monocytes isolated from healthy donors and treated with 1α,25(OH) 2 D 3 revealed the differential expression of several metabolism-related genes 15 , among which PFKFB4 (Fig. 1A) . PFKFB4 mRNA levels were already highly induced at 4 hours (7.6-fold increase) and 24 hours (8.1-fold increase) after 1α,25(OH) 2 D 3 treatment (Fig. 1B) . These data imply that in human monocyte- Fig. 1A) . 20 This effect on gene expression levels was only observed for the PFKFB4 isoform and not for PFKFB1
( Supplemental Fig. 1B) or PFKFB2 (Supplemental Fig. 1C ), which were hardly expressed in human differentiating monocytes at 24 hours (evidenced by very high Ct values) or PFKFB3, which showed a slight decrease in mRNA levels 4 hours after 1α,25(OH) 2 D 3 treatment (Fig. 1C) . The expression levels of TP53-inducible glycolysis and apoptosis regulator (TIGAR), the counteracting enzyme of PFKFB4, which dephosphorylates F-2,6-BP to fructose-6-phosphate, was marginally upregulated at 4 hours, but downregulated 24 hours after 1α,25(OH) 2 D 3 exposure (Fig. 1D) . Also, gene expression of PFK-1 was clearly upregulated by 1α,25(OH) 2 D 3 ( Fig. 1E) . Whereas increased PFKFB4 expression levels were confirmed on protein level, only a trend for increased PFK-1 protein could be observed (Fig. 1F) . Still, 1,25D 3 -DCs showed a significant higher PFK activity compared to control cells (Fig. 1G) . Taken together, these data indicate that PFKFB4 is a direct transcriptional target of 1α,25(OH) 2 D 3 which is early and strongly upregulated in 1,25D 3 -DCs.
1,25D 3 -DCs rely on glucose availability and usage for their tolerogenic phenotype. 15 Here we verified that 1,25D 3 -DCs consumed high amounts of glucose, which was evidenced by a decrease in the medium glucose content over the entire culture period (Supplemental Fig. 2A) . Simultaneously, these 1,25D 3 -DCs produced increased amounts of lactate (Supplemental Fig. 2B ) compared to control DCs. In line with this, 1,25D 3 -DCs presented with an enhanced glycolytic flux rate as compared to the control condition (Supplemental Fig. 2C ).
Aside from an accelerated glycolysis, 1,25D 3 -DCs showed a more than 2-fold increase in basal oxygen consumption rate (OCR) (Supplemental Fig. 2D and E) .
To get an unbiased insight into the glucose usage of 1,25D 3 -DCs, tracer metabolomics was performed.
Specifically, universally labeled [ (Fig. 1I) . Interestingly, the M+3 isotopologue of malate, and subsequently citrate (M+5), α-ketoglutarate and glutamate (M+4), was also 3A) . Exposure to 1α,25(OH) 2 D 3 enhanced the formation of F-2,6-BP, while addition of 5-MPN prevented the increase in F-2,6-BP levels ( Fig. 2A) as well as the rise in PFK activity (Fig. 2B) induced by 1α,25(OH) 2 D 3 .
A C C E P T E D M
A N U S C R I P T metabolism as described above, evidenced by an elevated glucose usage (Fig. 2C , left) and lactate production (Fig. 2D, left) . When PFKFB4 activity was inhibited by 5-MPN, a reduction in glucose consumption (Fig. 2C, right) and lactate production (Fig. 2D, right) by the 1,25D 3 -DCs was observed. In line with this, a decrease in the glycolytic flux, normally enhanced by 1α,25(OH) 2 D 3 , was noted in case of 5-MPN treatment (Fig. 2E) .
Moreover, the high basal OCR of 1,25D 3 -DCs was lowered by 5-MPN (Fig. 2F, Supplemental Fig. 3C ), suggesting a decrease in glucose oxidation and OXPHOS.
In addition, we performed [ (Fig. 2D) , this was not evident in the 13 C-labeling of lactate. Of note, no compensatory upregulation of PFKFB4, other PFKFB isoforms (Supplemental Fig. 3D ) or other metabolic genes (i.e. HK3, LDHA, PDHA1 and ATP5A1; data not shown) was observed upon PFKFB4 inhibition by 5-MPN. Taken together, these data indicate that 5-MPN is able to inhibit PFKFB4 activity, hereby strongly reducing 1,25D 3 -induced upregulated glucose metabolism, and in particular glucose oxidation, in 1,25D 3 -DCs.
PFKFB4 inhibition alters the induction of characteristic phenotypical and functional alterations of dendritic cells by 1α,25(OH) 2 D 3 .
Next, we investigated the impact of PFKFB4 inhibition by 5-MPN treatment on the 1,25D 3 -DC phenotype in vitro. Upon activation (i.e. with LPS and IFN-γ), control DCs cultured in DMSO had a spherical shape and formed big, non-adherent clusters in culture. In contrast, 1α,25(OH) 2 D 3 induced spindle-shaped morphological changes in mature DCs, which were not altered upon 5-MPN treatment (Fig. 3A) . The expression of the A C C E P T E D M A N U S C R I P T monocytic marker CD14 was retained in 1,25D 3 -DCs. In addition, 1,25D 3 -DCs displayed the typical tolerogenic maturation-resistant phenotype with reduced surface expression of the antigen-presenting molecules HLA-DR and CD1a and the co-stimulatory molecules CD80 and CD86 (Fig. 3B) . Inhibition of PFKFB4 activity did not interfere with the 1α,25(OH) 2 D 3 -mediated downregulation of these antigen-presenting and co-stimulatory molecules (Fig. 3B) . Concerning the surface marker CD80, 5-MPN treatment even reduced its expression to a greater extent.
The inhibitory molecule ILT-3 as well as the newly identified tolerogenic marker CD52 were increased 6.9-and 4.8-fold, respectively, at the cell surface of 1,25D 3 -DCs cultured with DMSO ( Fig. 3B) . High expression of ILT-3
has been described as a general feature of tolDCs. Moreover, surface expression of CXCR3, responsible for homing to inflammatory sites, was upregulated in 1,25D 3 -DCs cultured in DMSO, while the chemokine receptor CCR7 was similarly expressed as in control DCs, still allowing these cells to migrate to the lymphoid tissues (Fig. 3B) . Next, cytokine secretion patterns were investigated. As expected, 1,25D 3 -DCs treated with DMSO had decreased IL-12p70 and elevated IL 10, TNF-α and TGF-β secretion levels (Fig. 3C) . 5-MPN did not affect the 1α,25(OH) 2 D 3 -mediated reduction in IL-12p70 secretion (Fig. 3C) . However, the increase in IL-10, TNF-α and TGF-3 -DCs, was abrogated upon 5-MPN treatment. Of note, PFKFB4 inhibition in control DCs also affected the surface marker expression of CD1a, CD80, ILT-3 and CXCR3 as well as strongly increased the production of both IL-10, TNF-α and TGF-β in itself. We also found that 1,25D 3 -DCs produced higher amounts of indoleamine-2,3-dioxygenase (IDO), an enzyme that catabolizes the essential amino acid tryptophan (Fig. 3D) (Fig. 4A) . Addition of control DCs cultured in DMSO stimulated the proliferative capacity of both CD4 + and CD8 + allogeneic T cells with a respective 3-and 7-fold increase, which was reduced to at least half when the DCs were pre-treated with 1α,25(OH) 2 D 3 , irrespective of 5 MPN-mediated inhibition of PFKFB4 (Fig. 4A) . In line with this, the reduced production of the typical Th1 cytokine IFN-γ by T cells exposed to 1,25D 3 -DCs was unaffected by 5-MPN (Fig. 4B) . These observations were not surprising as 5-MPN treatment did not interfere with the 1α,25(OH) 2 D 3 -mediated downregulation of antigen-presentation, co-stimulation and the stimulatory cytokine production as described above (Fig. 4B, Fig. 4C ). Interestingly, the increased IL-10 secretion in the supernatant of co-cultures with DMSO-treated 1,25D 3 -DCs, was absent when DCs were treated with 5-MPN (Fig. 4C) . Of note, as IL-10 cytokine levels were determined in the co-culture supernatant, distinguishing between the IL-10 produced by DCs or by T cells is impossible with our method used. (Fig. 4D) , while no increase in T regulatory type 1 (T R 1) cells, characterized by CD49b and LAG3 co-expression (Fig. 4E) , was observed.
Although PFKFB4 inhibition did not affect the capacity of 1,25D 3 -DCs to induce these Tregs, it dramatically affected their functionality. Tregs primed in the presence of DMSO-treated 1,25D 3 -DCs potently suppressed (by 32.3%) the proliferation of responder T cells on challenge with allogeneic mature stimulator DCs compared to Teff cells primed with DMSO-treated control DCs (Fig. 4F, left) . The mature stimulator DCs were generated from the same donor as 1,25D 3 -DCs, which allowed us to test antigen specificity. In contrast, when 1,25D 3 -DCs Although not completely surprising, 5-MPN treatment also affected the expression of some surface markers and cytokines in control DCs. We hypothesized that this observation might correlate with the increased F-2,6-BP levels and increased glycolytic flux also detected in these 5-MPN-treated control DCs, suggesting that the regulation of these parameters indeed requires enhanced glycolysis.
In our previous study, full inhibition of glycolysis by 2-deoxy-glucose (2-DG) prevented the 1α,25(OH) 2 D 3 -mediated downregulation of antigen-presentation and costimulation, resulting in increased T cell stimulation.
Here, we did not observe similar effects on surface expression of HLA-DR, CD80 nor of CD86 when the glycolytic flux was reduced, but not blocked, by 5-MPN treatment. Although lactate secretion by 5-MPNtreated DCs was diminished, this was not evident from the metabolic tracing experiments. This discrepancy might be explained by the fact that only tracing into intracellular lactate, and not into the secreted lactate, was determined. However, strongly decreased labeling in TCA cycle metabolites indicated that mainly glucose
oxidation was limited upon PFKFB4 inhibition. Secreted lactate potentially provides an additional autocrine mechanism to induce an anti-inflammatory profile in human DCs. 30 Therefore, it is possible that 1,25D 3 -DCs try to maintain lactate production at the cost of glucose oxidation. When cells were cultured in low oxygen levels, the 1α,25(OH) 2 D 3 -mediated effects on HLA-DR, CD80 and CD86 surface expression, IL-10/IL-12 cytokine ratio and T cell proliferation were not affected. 15 In contrast, others described that human monocyte-derived tolDCs, generated in the presence of dexamethasone and 1α,25(OH) 2 D 3 , showed a metabolic profile in which OXPHOS and fatty acid oxidation were crucial. 31 However, we previously showed that there were no alterations in surface marker expression, cytokine production or T cell stimulatory capacity of 1,25D 3 -DCs upon inhibition of fatty acid oxidation. 15 In addition, our current data suggests that some parameters such as the inhibitory molecule ILT-3 or the tolerogenic marker CD52 are specifically regulated by glucose oxidation, while others, like the antigen-presenting molecule HLA-DR, are not.
Several studies in cancer cells have shown that PFKFB4 activity enhances glycolytic flux rate by increasing F-2,6-BP levels. 22, 32 In 1,25D 3 -DCs, we also detected enhanced PFKFB4 activity, resulting in elevated F-2,6-BP levels stimulating the glycolytic flux. In addition to its role in the glycolytic pathway, PFKFB4 controls embryonic patterning through Akt signaling and this independently from glycolysis. 33 We previously demonstrated that 1α,25(OH) 2 D 3 depends on the PI3K/Akt/mTOR axis to induce and maintain a tolerogenic phenotype in human 1,25D 3 -DCs. 15 Although we and others showed a direct role for PFKFB4 in glycolysis, it is possible that PFKFB4
regulates cellular metabolism at an additional level by controlling Akt phosphorylation.
Our current data are in line with previous reports describing the 1α,25(OH) 2 D 3 -mediated changes in morphology, surface marker expression, migratory profile and cytokine secretion of DCs. 8, 11, 15, 26, [34] [35] [36] In addition, higher expression of CD52, a surface glycoprotein recently proposed as a new biomarker for tolDCs, 23 was validated. In contrast to Unger et al. 11 where no increase in IDO activity was observed, we reported here a 60% increase in IDO protein secreted by 1,25D 3 -DCs. Interestingly, inhibition of histone deacetylation increases IDO expression in human DCs. 37 Moreover, the enzyme Sirtin, responsible for histone deacetylation, was downregulated as evidenced in the microarray analysis performed in human differentiating monocytes Given the interesting characteristics of tolDCs to induce antigen-specific protection, cellular immunotherapies with autologous antigen-loaded tolDCs provide a promising therapy for autoimmune diseases. Currently, the In sum, our findings further strengthen the essential role of glucose metabolism in the generation of human 1,25D 3 -DCs and specifically unravel the necessity of glucose oxidation in the induction of functional Tregs by 1,25D 3 -DCs. From a broader perspective, these data provide further evidence for the concept that PFKFB4 is an essential regulator of glucose metabolism, which is induced by 1α,25(OH) 2 D 3 and is responsible for the establishment of DC tolerogenicity.
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